Kenvue Inc. (NYSE:KVUE) Stake Raised by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 35.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,816 shares of the company’s stock after buying an additional 22,058 shares during the period. Transcend Capital Advisors LLC’s holdings in Kenvue were worth $1,826,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Clearstead Advisors LLC bought a new stake in Kenvue during the third quarter worth approximately $25,000. Planned Solutions Inc. bought a new stake in Kenvue during the fourth quarter worth approximately $27,000. Global Retirement Partners LLC bought a new stake in Kenvue during the third quarter worth approximately $28,000. Venturi Wealth Management LLC bought a new stake in Kenvue during the third quarter worth approximately $28,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Kenvue during the third quarter worth approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.8 %

NYSE KVUE traded down $0.16 on Friday, hitting $18.86. 15,454,689 shares of the stock were exchanged, compared to its average volume of 13,458,618. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $19.84 and its two-hundred day moving average price is $20.13.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue’s revenue was down 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank of Canada dropped their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. JPMorgan Chase & Co. dropped their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. Finally, William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.